Sepsis, ghrelin, the cholinergic anti-inflammatory pathway, gut mucosal hyperpermeability, and high-mobility group box 1.
Fink
Mitchell P
MP
D000818:Animals; D018680:Cholinergic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D054439:Ghrelin / Q000494:pharmacology* / Q000627:therapeutic use; D024243:HMGB1 Protein / Q000037:antagonists & inhibitors*; D006801:Humans; D007249:Inflammation / Q000503:physiopathology / Q000517:prevention & control*; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000378:metabolism; D010539:Permeability; D051381:Rats; D018805:Sepsis / Q000188:drug therapy*
D018680:Cholinergic Antagonists; D054439:Ghrelin; D024243:HMGB1 Protein